[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trigger-point-in-trapezius-muscle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trigger-point-in-trapezius-muscle":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100635047","phase-4-prp-vs-prpbetamethasone-vs-betamethasone-injection-for-upper-trapezius-myofascial-pain-100635047",false,"NCT07547605","PRP vs PRP+Betamethasone vs Betamethasone Injection for Upper Trapezius Myofascial Pain","Comparison of Platelet-Rich Plasma, Combined Platelet-Rich Plasma Plus Betamethasone, and Betamethasone Monotherapy Trigger Point Injections in Patients With Upper Trapezius Myofascial Pain Syndrome: A Prospective, Randomized, Assessor-Blind, Controlled Trial","UMAY-RCT","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Presentation to the Orthopedics and Traumatology outpatient clinic with neck and\u002For shoulder pain\n* Diagnosis of upper trapezius myofascial pain syndrome based on Simons and Travell criteria, including:\n* Presence of a taut band\n* Local tenderness\n* Referred pain pattern\n* Local twitch response\n* Presence of a single active trigger point in the upper trapezius muscle\n* Symptom duration ≥ 4 weeks\n* Pain intensity ≥ 4 on the visual analog scale (VAS)\n* Inadequate response to at least 4 weeks of conservative treatment (physical therapy and\u002For oral analgesics)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of multiple active trigger points\n* Diagnosis of fibromyalgia according to ACR 2010 criteria\n* Cervical radiculopathy or myelopathy\n* Trigger point injection in the same region within the past 3 months\n* Coagulopathy or current anticoagulant or antiplatelet therapy\n* Known allergy or contraindication to corticosteroids, local anesthetics, or PRP components\n* Active infection (systemic or local)\n* Pregnancy or lactation\n* Thrombocytopenia (platelet count \\\u003C 100,000\u002FµL)\n* Malignancy\n* Inability to cooperate or provide informed consent","ALL","18 Years","65 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Brief Summary\n\nMyofascial pain syndrome (MPS) is a common musculoskeletal condition characterized by active trigger points (TrPs), which are hypersensitive, painful nodules within taut bands of skeletal muscle. The upper trapezius muscle is one of the most frequently affected sites. Trigger point injection (TPI) is a widely used minimally invasive treatment for patients who are refractory to conservative management.\n\nCorticosteroids provide rapid anti-inflammatory effects, whereas platelet-rich plasma (PRP) has regenerative properties through growth factors that may support tissue healing. Despite their widespread use, the optimal injectate for TPI remains unclear. Additionally, the potential benefit of combining PRP with corticosteroids has not been adequately studied in upper trapezius MPS.\n\nThis study is a single-center, prospective, randomized, assessor-blinded controlled trial designed to compare the clinical effectiveness of three injection protocols: (1) PRP plus bupivacaine, (2) PRP plus betamethasone plus bupivacaine, and (3) betamethasone plus bupivacaine with saline (volume-matched control). A total of 150 patients with a single active trigger point in the upper trapezius will be included.\n\nThe primary outcome is pain intensity measured by the visual analog scale (VAS) at 3 months. Secondary outcomes include pressure pain threshold (PPT), cervical range of motion (ROM), rescue analgesic use, recurrence rate, and adverse events at 1 week, 4 weeks, 3 months, and 6 months.\n\nAll injections are performed by the same investigator using a palpation-guided technique, and outcome assessments are conducted by a blinded evaluator.",[28,29,30],"Myofascial Pain Dysfunction Syndrome","Trigger Points, Myofascial","Trigger Point in Trapezius Muscle",[32,33,34,35,36,37,38,39],"platelet-rich plasma","PRP","betamethasone","trigger point injection","myofascial pain syndrome","trapezius","randomized controlled trial","pressure pain threshold","RECRUITING","2026-06-14",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":44},"2026-05-15",{"date":48,"type":22},"2027-01",{"name":50,"class":51},"University of Kyrenia","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100613721","the-impact-of-dry-needling-on-electrophysiological-and-ultrasound-based-biomarkers-for-myofascial-pain-100613721","NCT07270276","The Impact of Dry Needling on Electrophysiological and Ultrasound-based Biomarkers for Myofascial Pain","ENCOMPASS-2","Inclusion Criteria:\n\n* Ages 18-80\n* Presence of active trigger points with involvement of upper trapezius\n* Able to manage breakthrough pain with acetaminophen only, excluding stable doses of pain medications at time of enrollment, which can be continued\n\nExclusion Criteria:\n\n* Multiple active trigger points in the trapezius muscle if physician assessment concludes that this may interfere with subject's ability to detect changes in pain improvement from trigger point therapy\n* Presence of cervical radicular pain, superimposed neuromuscular disease or condition that, in the opinion of the investigator, could confound interpretation of the data acquired from trapezius.\n* Fibromyalgia or other generalized pain condition\n* Opioid usage in the past 3 months\n* Active substance use disorder\n* Not on a stable dose for at least two weeks prior to study enrollment or unwilling to maintain a stable dose for duration of the study of the following drugs:\n\n  1. SSRIs, such as citalopram, escitalopram, fluoxetine, sertraline,\n  2. SNRIs, such as duloxetine, milnacipran, and venlafaxine\n  3. Tricyclic antidepressants, such as notritptyline, amitriptyline, and desipramine\n  4. Alpha 2 delta ligands: pregabalin, gabapentin\n  5. Specific anti-epileptics: topiramate, lamotrigine, oxcarbazepine, and phenytoin\n  6. Other: quinidine, mexiletine, and dalfampridine\n* Skin allergy or sensitivity that would preclude the use of adhesive electrodes\n* Significant systemic or psychiatric illness that in the opinion of the site Investigator would interfere with the individual's ability to participate in the trial\n* Anticoagulation (with coumadin, clopidogrel, or direct oral anticoagulants; aspirin acceptable)\n* TrP needle-based therapy in the past six weeks of the TrP to be studied\n* Body mass index \\> 35 kg\u002Fm2\n* Other factor that in the opinion of the site investigator would interfere with the ability to perform the study procedures","80 Years",{"count":61,"type":22},70,[63],"NA","The goal of this interventional study is to determine how well dry-needling can treat pain in people with Myofascial Pain Syndrome. The main questions it aims to answer are:\n\n* Does dry needling improve pain for people with a trigger point (a tender, tight spot in the muscle)?\n* How well can Electrical Impedence Myography (EIM), Myofiber Threshold Tracking (TT), and Ultrasound (US) detect changes in the muscle related to dry needling treatment?\n\nResearchers will compare dry needling to a placebo (a treatment that does not enter the trigger point) to see if dry needling works to treat Myofascial Pain Syndrome with trigger points in the trapezius muscle (the muscle that extends over the back of the neck and shoulders), as measured by these three outcome measures (EIM, US, TT).\n\nParticipants will:\n\n* Visit the clinic twice: once to receive dry needling treatment, and once for a follow-up\n* Have muscle measurements taken before treatment and at follow-up\n* Have a daily survey to record the intensity of their pain",[30],[67,68,69,70],"Myofascial Pain","Trigger Point","Myofascial Pain Syndrome","Trapezius Muscle Pain","2026-02-22",{"date":73,"type":44},"2026-02-24",{"date":75,"type":44},"2026-02-01",{"date":77,"type":22},"2028-08-31",{"name":79,"class":51},"Beth Israel Deaconess Medical Center"]